Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, afatinib (Giotrif®) cannot be endorsed for use within NHS Wales for the treatment of locally advanced or metastatic non-small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy. |
||
|
||
Medicine details |
||
| Medicine name | afatinib (Giotrif®) | |
| Formulation | 20 mg, 30 mg, 40 mg and 50 mg film-coated tablet | |
| Reference number | 1720 | |
| Indication | Treatment of locally advanced or metastatic non-small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy. |
|
| Company | Boehringer Ingelheim Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 26/07/2016 | |